Phase 1/2 study of HUB-101
Latest Information Update: 16 Oct 2024
At a glance
- Drugs HUB 101 (Primary)
- Indications Leber congenital amaurosis
- Focus Therapeutic Use
- 16 Oct 2024 New trial record
- 09 Oct 2024 According to an Andelyn Biosciences, Inc media release, HUB-101 has received Rare Pediatric Disease Designation and Orphan Disease Designation from the FDA for this program.